Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amplia Therapeutics ( (AU:ATX) ) just unveiled an update.
Amplia Therapeutics has announced positive interim data from its ACCENT trial, which is evaluating the efficacy of its FAK inhibitor, narmafotinib, in combination with standard chemotherapies for advanced pancreatic cancer. The trial results show significant improvements in progression-free survival and objective response rates compared to chemotherapy alone, indicating a promising advancement in treatment options for pancreatic cancer patients. The company is preparing for a potential pivotal phase 2b/3 trial, which could enhance its position in the oncology market and offer new hope for stakeholders in the healthcare sector.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is a biotechnology company focused on developing innovative treatments for cancer. The company specializes in the development of FAK inhibitors, with its lead product, narmafotinib, being investigated for its efficacy in treating advanced pancreatic cancer.
Average Trading Volume: 7,163,090
Technical Sentiment Signal: Buy
Current Market Cap: A$111.9M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.